Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry

被引:0
|
作者
Bidin, Mohamed Badrulnizam Long [1 ]
Khan, Abdul Mueed [2 ]
Tan, Florence Hui Sieng [3 ]
Aziz, Nor Azizah [4 ]
Ali, Norhaliza Mohd [5 ]
Kamaruddin, Nor Azmi [6 ]
Vethakkan, Shireene Ratna [7 ]
Sethi, Balraj [2 ]
Hussein, Zanariah [8 ]
机构
[1] Hosp Kuala Lumpur, Jalan Pahang, Kuala Lumpur, Malaysia
[2] Novartis Corp, M Sdn Bhd, Petaling Jaya, Selangor, Malaysia
[3] Hosp Umum Sarawak, Sarawak, Malaysia
[4] Hosp Pulau Pinang, George Town, Malaysia
[5] Hosp Sultanah Aminah Johor Bahru, Johor Baharu, Malaysia
[6] Hosp Canselor Tuanku Muhriz UKM, Kuala Lumpur, Malaysia
[7] Pusat Perubatan Univ Malaya, Kuala Lumpur, Malaysia
[8] Hosp Putrajaya, Pusat Pentadbiran Kerajaan Persekutuan,Presint 7, Putrajaya 62250, Malaysia
来源
JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES | 2023年 / 38卷 / 01期
关键词
acromegaly; Malaysian registry; healthcare resource utilization; treatment outcomes; CLINICAL-PRACTICE; PREVALENCE; COMPLICATIONS; MANAGEMENT; DIAGNOSIS;
D O I
10.15605/jafes.038.01.06
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia. Methodology. This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained. Results. Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 - 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%). Conclusion. This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 50 条
  • [21] Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
    Miyazaki, Celine
    Ishii, Yukata
    Stelmaszuk, Natalia M.
    CLINICAL RHEUMATOLOGY, 2022, 41 (03) : 741 - 755
  • [22] Adherence to Acromegaly Treatment and Analysis of the Related Factors-A Real-World Study in Bulgaria
    Kamusheva, Maria
    Vandeva, Silvia
    Mitov, Konstantin
    Parvanova, Alexina
    Pesheva, Marina
    Ganov, Nikolay
    Rusenova, Yanitsa
    Marinov, Lyubomir
    Getova, Violeta
    Elenkova, Atanaska
    Petrova, Guenka
    PHARMACEUTICS, 2023, 15 (02)
  • [23] Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study
    Bolanowski, Marek
    Hubalewska-Dydejczyk, Alicja
    Kos-Kudla, Beata
    Ruchala, Marek
    Witek, Przemyslaw
    Zgliczynski, Wojciech
    Houchard, Aude
    Bartmanska, Marta
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (05) : 512 - 519
  • [24] Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
    Marques, Nelma Veronica
    Wildemberg, Luiz Eduardo Armondi
    Gadelha, Monica R.
    ENDOCRINE CONNECTIONS, 2023, 12 (10)
  • [25] Disease Burden, Treatment Patterns and Asthma Control in Adult Patients with Asthma in China: A Real-World Study
    Benson, Victoria S.
    Siddall, James
    Haq, Adam
    Small, Mark
    Alfonso-Cristancho, Rafael
    Tang, Zhiliu
    Howarth, Peter
    Ye, Tao
    Richards, Anna
    JOURNAL OF ASTHMA AND ALLERGY, 2024, 17 : 949 - 964
  • [26] Real-world epidemiology, treatment patterns and disease burden of patients diagnosed with chronic hepatitis B in Taiwan
    Chien, Hsiu-Ting
    Su, Tung-Hung
    Huang, Hazel
    Chiang, Chih-Lin
    Lin, Fang-Ju
    LIVER INTERNATIONAL, 2023, : 2404 - 2414
  • [27] Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific ProgrammeTM
    Zhao, Hongru
    Xiao, Zheman
    Zhang, Lei
    Ford, Janet
    Zhong, Shiying
    Ye, Wenyu
    Li, Jinnan
    Tockhorn-Heidenreich, Antje
    Cotton, Sarah
    Chen, Chunfu
    JOURNAL OF PAIN RESEARCH, 2023, 16 : 357 - 371
  • [28] The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
    Witek, Przemyslaw
    Bolanowski, Marek
    Szamotulska, Katarzyna
    Wojciechowska-Luzniak, Agnieszka
    Jawiarczyk-Przybylowska, Aleksandra
    Kaluzny, Marcin
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [29] Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice
    Xu, Xiao
    Kwiatek, Justin
    Siddall, James
    Genofre, Eduardo
    Stirnadel-Farrant, Heide
    Katial, Rohit
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [30] Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan
    Fukuda, Naoki
    Tanizawa, Yoshinori
    Nakamura, Kenichi
    Okada, Yui
    Segall, Grace
    Kiiskinen, Urpo
    Fasnacht, Nicolas
    Sanderson, Isaac
    Rider, Alex
    Lewis, Katie
    FUTURE ONCOLOGY, 2023, 19 (16) : 1125 - 1137